Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes

Incretin hormone dysregulation contributes to reduced insulin secretion and hyperglycemia in patients with type 2 diabetes mellitus (T2DM). Resistance to glucose-dependent insulinotropic polypeptide (GIP) action may occur through desensitization or downregulation of β-cell GIP receptors (GIP-R). Studies in rodents and cell lines show GIP-R expression can be regulated through peroxisome proliferator–activated receptor γ (PPARγ) response elements (PPREs). Whether this occurs in humans is unknown. To test this, we conducted a randomized, double-blind, placebo-controlled trial of pioglitazone therapy on GIP-mediated insulin secretion and adipocyte GIP-R expression in subjects with well-controlled T2DM. Insulin sensitivity improved, but the insulinotropic effect of infused GIP was unchanged following 12 weeks of pioglitazone treatment. In parallel, we observed increased GIP-R mRNA expression in subcutaneous abdominal adipocytes from subjects treated with pioglitazone. Treatment of cultured human adipocytes with troglitazone increased PPARγ binding to GIP-R PPREs. These results show PPARγ agonists regulate GIP-R expression through PPREs in human adipocytes, but suggest this mechanism is not important for regulation of the insulinotropic effect of GIP in subjects with T2DM. Because GIP has antilipolytic and lipogenic effects in adipocytes, the increased GIP-R expression may mediate accretion of fat in patients with T2DM treated with PPARγ agonists.

[1]  Andrea Mari,et al.  A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test , 2001 .

[2]  C. Mcintosh,et al.  Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. , 2009, Human molecular genetics.

[3]  J. Holst,et al.  Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[4]  T. Kieffer,et al.  Targeting the glucagon receptor family for diabetes and obesity therapy. , 2012, Pharmacology & therapeutics.

[5]  Tanya Hansotia,et al.  Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. , 2007, The Journal of clinical investigation.

[6]  H. Hauner,et al.  Primary culture of human adipocyte precursor cells: expansion and differentiation. , 2012, Methods in molecular biology.

[7]  T. Vilsbøll,et al.  Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes , 2009, Diabetologia.

[8]  C. Mcintosh,et al.  Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression* , 2005, Journal of Biological Chemistry.

[9]  R. Pederson,et al.  Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. , 2001, Diabetes.

[10]  J. Leahy,et al.  Physiologic and Pharmacologic Modulation of Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Expression in β-Cells by Peroxisome Proliferator–Activated Receptor (PPAR)-γ Signaling , 2010, Diabetes.

[11]  Peter J Moate,et al.  MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. , 2003, Diabetes technology & therapeutics.

[12]  J. Holst,et al.  Incretins, insulin secretion and Type 2 diabetes mellitus , 2004, Diabetologia.

[13]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  J. Holst,et al.  Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. , 1998, Diabetes.

[15]  J. Holst,et al.  Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. , 2017, American journal of physiology. Endocrinology and metabolism.

[16]  R. Gimeno,et al.  Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial , 2018, The Lancet.

[17]  F. Tinahones,et al.  Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. , 2014, The Journal of clinical endocrinology and metabolism.

[18]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[19]  任艳,et al.  胰岛素增敏剂一Thiazolidinediones研究现状 , 2000 .

[20]  J. Holst,et al.  The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. , 2011, American journal of physiology. Endocrinology and metabolism.

[21]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[22]  S. Del Prato,et al.  Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors , 2017, Diabetes, obesity & metabolism.

[23]  Robert R. Henry,et al.  Prevention of Diabetes With Pioglitazone in ACT NOW , 2013, Diabetes.

[24]  S. Bonner-Weir,et al.  Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia , 2007, Diabetes.

[25]  C. Mcintosh,et al.  Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARγ and histone acetylation , 2011, Journal of Lipid Research.

[26]  M. Tschöp,et al.  Reappraisal of GIP Pharmacology for Metabolic Diseases. , 2016, Trends in molecular medicine.

[27]  R N Bergman,et al.  Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. , 1990, The Journal of clinical endocrinology and metabolism.

[28]  H. Hendrickson Prevention of what? , 1983, Journal of the American Optometric Association.

[29]  R. Hovorka,et al.  ISEC: a program to calculate insulin secretion. , 1996, Computer methods and programs in biomedicine.

[30]  D. Taura,et al.  Inhibition of Gastric Inhibitory Polypeptide Receptor Signaling in Adipose Tissue Reduces Insulin Resistance and Hepatic Steatosis in High-Fat Diet–Fed Mice , 2017, Diabetes.

[31]  M. Lazar,et al.  Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. , 2005, Genes & development.

[32]  A. Pfeiffer,et al.  GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women , 2007, Regulatory Peptides.

[33]  D. Drucker,et al.  Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.

[34]  J. Holst,et al.  Transgenic Rescue of Adipocyte Glucose-dependent Insulinotropic Polypeptide Receptor Expression Restores High Fat Diet-induced Body Weight Gain* , 2011, The Journal of Biological Chemistry.

[35]  Devjit Tripathy,et al.  Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.

[36]  J. Holst,et al.  Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects , 2003, Regulatory Peptides.

[37]  C. Mcintosh,et al.  Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes , 2007, Journal of Biological Chemistry.

[38]  C. Mcintosh,et al.  Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). , 2009, Vitamins and hormones.

[39]  Yuichiro Yamada,et al.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.

[40]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[41]  L. Groop,et al.  Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance , 2013, Diabetes.

[42]  Bin Yang,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[43]  V. Fonseca Effect of thiazolidinediones on body weight in patients with diabetes mellitus. , 2003, The American journal of medicine.

[44]  C. Mcintosh,et al.  GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene , 2010, Journal of Lipid Research.

[45]  E. Mazzaferri,et al.  Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. , 1975, The Journal of clinical endocrinology and metabolism.

[46]  J. Holst,et al.  Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients , 2002, Diabetologia.